Obama Cools the Stem-Cell Debate
By Jesse Reynolds,
San Francisco Chronicle
| 04. 27. 2009
While juggling a collapsing economy and major initiatives during his first months in office, President Obama tackled - and cooled - a contentious issue that has simmered for almost 10 years: embryonic stem cell research. His March 9 executive order fulfilled a campaign promise to lift his predecessor's restrictions on its federal funding.
The president outlined his new approach, leaving the details up to the National Institutes of Health. A week ago, the NIH unveiled its draft guidelines.
The new regulations would permit federal support for research with stem cell lines derived from embryos that are created, but not used, for fertility treatments. There are hundreds of thousands of such excess embryos in storage, most scheduled for eventual destruction regardless of scientists' activities. At the same time, federal support would not be permitted for work with stem cell lines derived from embryos created with cloning techniques - if any are ever successfully produced.
This is a thoughtful approach, and the right thing to do.
There are very good reasons - technical, ethical and political - why cloning-based stem cell research...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...